Insulin delivery devices in diabetes management: Applications and advancements

Abstract

With continuous advancements in diabetes management technology, insulin delivery devices have become increasingly central to the treatment of diabetes. This review discusses the applications and development of various insulin delivery technologies, including insulin pens and pumps, in the management of type 1 diabetes (T1DM) and type 2 diabetes (T2DM). Insulin pens are widely used among individuals with T2DM due to their ease of use and dosing accuracy. The recent development of smart insulin pens has further enhanced patient adherence and glycemic control. Insulin pumps, particularly patch pumps, provide more precise glucose management for individuals with T1DM and select T2DM patients, significantly reducing glycemic variability and the risk of hypoglycemia. Patch pumps, as an innovative insulin infusion device, are particularly suitable for patients requiring discreet and convenient use, owing to their compact, lightweight, and tubeless design. This is especially pertinent for the large population of individuals with T2DM. However, mechanical patch pumps still require further optimization, particularly in displaying infusion volume and key operational parameters, to facilitate realtime monitoring and timely therapeutic adjustments by both patients and clinicians. This review summarizes the advantages and limitations of different types of insulin delivery devices and explores their potential role in clinical practice. Further advancements in these systems are expected to offer safer, more convenient, precise, and costeffective treatment options for diabetes management.

Keywords

Diabetes / Insulin delivery device / Insulin pen / Insulin pump / Mechanical insulin patch pump

References

[1] Sacks DB , Arnold M , Bakris GL , et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care. 2023; 46 (10): e151- e199.

[2] American Diabetes Association . Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014; 37 (Suppl 1): S81- S90.

[3] Atkinson MA , Eisenbarth GS , Michels AW . Type 1 diabetes. Lancet. 2014; 383 (9911): 69- 82.

[4] Januszewski AS , Cho YH , Joglekar MV , et al. Insulin micro-secretion in type 1 diabetes and related microrna profiles. Sci Rep. 2021; 11 (1): 11727.

[5] Mayer-Davis EJ , Kahkoska AR , Jefferies C , et al. ISPAD clinical practice consensus guidelines 2018:definition, epidemiology, and classification of diabetes in children and adolescents. Pediatr Diabetes. 2018; 19 (27): 7- 19. Suppl 27.

[6] Vanderniet JA , Jenkins AJ , Donaghue KC . Epidemiology of type 1 diabetes. Curr Cardiol Rep. 2022; 24 (10): 1455- 1465.

[7] Weyer C , Bogardus C , Mott DM , et al. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Investig. 1999; 104 (6): 787- 794.

[8] Reaven GM . Banting lecture 1988. role of insulin resistance in human disease. Diabetes. 1988; 37 (12): 1595- 1607.

[9] American Diabetes Association Professional Practice Committee . 2.diagnosis and classification of diabetes:standards of care in diabetes-2024. Diabetes Care. 2024; 47 (Suppl 1): S20- S42.

[10] Zheng Y , Ley SH , Hu FB . Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018; 14 (2): 88- 98.

[11] Zimmet PZ . Diabetes and its drivers:the largest epidemic in human history? Clinical Diabetes and Endocrinology. 2017; 3: 1.

[12] Bruno G , Runzo C , Cavallo-Perin P , et al. Incidence of type 1 and type 2 diabetes in adults aged 30-49 years:the population-based registry in the province of turin, Italy. Diabetes Care. 2005; 28 (11): 2613- 2619.

[13] Holman N , Young B , Gadsby R . Current prevalence of type 1 and type 2 diabetes in adults and children in the UK. Diabet Med:A Journal of the British Diabetic Association. 2015; 32 (9): 1119- 1120.

[14] Home PD , Bergenstal RM , Bolli GB , et al. Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 u/ml versus glargine 100 u/ml in people with type 1 diabetes. Diabetes Obes Metabol. 2018; 20 (1): 121- 128. edition 4.

[15] Gough SCL , Harris S , Woo V , et al. Insulin degludec:overview of a novel ultra longacting basal insulin. Diabetes Obes Metabol. 2013; 15 (4): 301- 309.

[16] Warren M , Bode B , Cho JI , et al. Improved postprandial glucose control with ultra rapid lispro versus lispro with continuous subcutaneous insulin infusion in type 1 diabetes:pronto-pump-2. Diabetes. Obes Metabol. 2021; 23 (7): 1552- 1561.

[17] Buse JB , Carlson AL , Komatsu M , et al. Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes:efficacy and safety from a randomized double-blind trial. Diabetes Obes Metabol. 2018; 20 (12): 2885- 2893.

[18] Shah RB , Patel M , Maahs DM , et al. Insulin delivery methods:past, present and future. International Journal of Pharmaceutical Investigation. 2016; 6 (1): 1- 9.

[19] Aronson R , Gibney MA , Oza K , et al. Insulin pen needles:effects of extra-thin wall needle technology on preference, confidence, and other patient ratings. Clin Ther. 2013; 35 (7): 923- 933.e4.

[20] Selam J-L . Evolution of diabetes insulin delivery devices. J Diabetes Sci Technol. 2010; 4 (3): 505- 513.

[21] Fry A . Insulin delivery device technology 2012:where are we after 90 years? J Diabetes Sci Technol. 2012; 6 (4): 947- 953.

[22] Retnakaran R , Hochman J , DeVries JH , et al. Continuous subcutaneous insulin infusion versus multiple daily injections:the impact of baseline a1c. Diabetes Care. 2004; 27 (11): 2590- 2596.

[23] Bruttomesso D , Pianta A , Crazzolara D , et al. Continuous subcutaneous insulin infusion (csii) in the veneto region:efficacy, acceptability and quality of life. Diabet Med:A Journal of the British Diabetic Association. 2002; 19 (8): 628- 634.

[24] Hanaire-Broutin H , Melki V , Bessières-Lacombe S , et al. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment:a randomized study. the study group for the development of pump therapy in diabetes. Diabetes Care. 2000; 23 (9): 1232- 1235.

[25] Jeitler K , Horvath K , Berghold A , et al. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus:systematic review and meta-analysis. Diabetologia. 2008; 51 (6): 941- 951.

[26] Fatourechi MM , Kudva YC , Murad MH , et al. Clinical review:hypoglycemia with intensive insulin therapy:a systematic review and meta-analyses of randomized trials of continuous subcutaneous insulin infusion versus multiple daily injections. J Clin Endocrinol Metabol. 2009; 94 (3): 729- 740.

[27] Boland EA , Grey M , Oesterle A , et al. Continuous subcutaneous insulin infusion. a new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes. Diabetes Care. 1999; 22 (11): 1779- 1784.

[28] Berthe E , Lireux B , Coffin C , et al. Effectiveness of intensive insulin therapy by multiple daily injections and continuous subcutaneous infusion:a comparison study in type 2 diabetes with conventional insulin regimen failure. Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme. 2007; 39 (3): 224- 229.

[29] Gao G-Q , Heng X-Y , Wang Y-L , et al. Comparison of continuous subcutaneous insulin infusion and insulin glargine-based multiple daily insulin aspart injections with preferential adjustment of basal insulin in patients with type 2 diabetes. Exp Ther Med. 2014; 8 (4): 1191- 1196.

[30] Choi S-B , Lee J-H , Lee J-H , et al. Improvement of β-cell function after achievement of optimal glycaemic control via long-term continuous subcutaneous insulin infusion therapy in non-newly diagnosed type 2 diabetic patients with suboptimal glycaemic control. Diabetes Metabol Res Rev. 2013; 29 (6): 473- 482.

[31] Kesavadev J , Saboo B , Krishna MB , et al. Evolution of insulin delivery devices:from syringes, pens, and pumps to diy artificial pancreas. Diabetes Therapy:Research, Treatment and Education of Diabetes and Related Disorders. 2020; 11 (6): 1251- 1269.

[32] Masierek M , Nabrdalik K , Janota O , et al. The review of insulin pens-past, present, and look to the future. Front Endocrinol. 2022; 13: 827484.

[33] Hyllested-Winge J , Sparre T , Pedersen LK . NovoPen echo(^®) insulin delivery device. Medical Devices (Auckland, N.Z.). 2016; 9: 11- 18.

[34] Ignaut DA , Venekamp WJ . HumaPen memoir:a novel insulin-injecting pen with a dose-memory feature. Expet Rev Med Dev. 2007; 4 (6): 793- 802.

[35] Berger AS , Saurbrey N , Kühl C , et al. Clinical experience with a new device that will simplify insulin injections. Diabetes Care. 1985; 8 (1): 73- 76.

[36] Klonoff D , Nayberg I , Rabbone I , et al. Evaluation of the juniorstar^® half-unit insulin pen in young people with type 1 diabetes-user perspectives. Eur Endocrinol. 2013; 9 (2): 82- 85.

[37] Olsen BS , Lilleøre SK , Korsholm CN , et al. Novopen echo^® for the delivery of insulin: a comparison of usability, functionality and preference among pediatric subjects, their parents, and health care professionals. J Diabetes Sci Technol. 2010; 4 (6): 1468- 1475.

[38] Sy SL , Munshi MM , Toschi E . Can smart pens help improve diabetes management? J Diabetes Sci Technol. 2020; 16 (3): 628- 634.

[39] Gildon BW . InPen smart insulin pen system:product review and user experience. Diabetes Spectr:A Publication of the American Diabetes Association. 2018; 31 (4): 354- 358.

[40] Heinemann L , Schnell O , Gehr B , et al. Digital diabetes management:a literature review of smart insulin pens. J Diabetes Sci Technol. 2022; 16 (3): 587- 595.

[41] Kesavadev J , Das AK , Unnikrishnan R , et al. Use of insulin pumps in India:suggested guidelines based on experience and cultural differences. Diabetes Technol Therapeut. 2010; 12 (10): 823- 831.

[42] Steineck I , Cederholm J , Eliasson B , et al. Insulin pump therapy, multiple daily injections, and cardiovascular mortality in 18 168 people with type 1 diabetes: observational study. Br Med J. 2015; 350: h3234.

[43] Waugh N , Adler A , Craigie I , et al. Closed loop systems in type 1 diabetes. Br Med J. 2018; 361: k1613.

[44] Mazzotta FA , Lucaccini Paoli L , Rizzi A , et al. The development and evolution of insulin pumps:from early beginnings to future prospects. Minerva Endocrinol. 2024; 49 (1): 85- 99.

[45] Deiss D , Adolfsson P , Alkemade-van Zomeren M , et al. Insulin infusion set use: european perspectives and recommendations. Diabetes Technol Therapeut. 2016; 18 (9): 517- 524.

[46] Schaepelynck P , Riveline J-P , Renard E , et al. Assessment of a new insulin preparation for implanted pumps used in the treatment of type 1 diabetes. Diabetes Technol Therapeut. 2014; 16 (9): 582- 589.

[47] Tauschmann M , Hovorka R . Technology in the management of type 1 diabetes mellitus-current status and future prospects. Nat Rev Endocrinol. 2018; 14 (8): 464- 475.

[48] Sherr JL , Hermann JM , Campbell F , et al. Use of insulin pump therapy in children and adolescents with type 1 diabetes and its impact on metabolic control: comparison of results from three large, transatlantic paediatric registries. Diabetologia. 2016; 59 (1): 87- 91.

[49] Szypowska A , Schwandt A , Svensson J , et al. Insulin pump therapy in children with type 1 diabetes:analysis of data from the sweet registry. Pediatr Diabetes. 2016; 17 (Suppl 23): 38- 45.

[50] Jones SM , Quarry JL , Caldwell-McMillan M , et al. Optimal insulin pump dosing and postprandial glycemia following a pizza meal using the continuous glucose monitoring system. Diabetes Technol Therapeut. 2005; 7 (2): 233- 240.

[51] Ramotowska A , Golicki D , Dzygało K , et al. The effect of using the insulin pump bolus calculator compared to standard insulin dosage calculations in patients with type 1 diabetes mellitus-systematic review. Experimental and Clinical Endocrinology & Diabetes. Official Journal, German Society of Endocrinology[and] German Diabetes Association. 2013; 121 (5): 248- 254.

[52] Pickup JC , Sutton AJ . Severe hypoglycaemia and glycaemic control in type 1 diabetes:meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med:A Journal of the British Diabetic Association. 2008; 25 (7): 765- 774.

[53] Yeh H-C , Brown TT , Maruthur N , et al. Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus:a systematic review and meta-analysis. Ann Intern Med. 2012; 157 (5): 336- 347.

[54] Monami M , Lamanna C , Marchionni N , et al. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 1 diabetes:a meta-analysis. Acta Diabetol. 2010; 47 (Suppl 1): 77- 81.

[55] Pańkowska E , Błazik M , Dziechciarz P , et al. Continuous subcutaneous insulin infusion vs. multiple daily injections in children with type 1 diabetes:a systematic review and meta-analysis of randomized control trials. Pediatr Diabetes. 2009; 10 (1): 52- 58.

[56] Błazik M , Pańkowska E . The effect of bolus and food calculator diabetics on glucose variability in children with type 1 diabetes treated with insulin pump:the results of rct. Pediatr Diabetes. 2012; 13 (7): 534- 539.

[57] Klonoff DC , Kerr D . Smart pens will improve insulin therapy. J Diabetes Sci Technol. 2018; 12 (3): 551- 553.

[58] Peyrot M , Barnett AH , Meneghini LF , et al. Insulin adherence behaviours and barriers in the multinational global attitudes of patients and physicians in insulin therapy study. Diabet Med. 2012; 29 (5): 682- 689.

[59] Umpierrez GE , Klonoff DC . Diabetes technology update:use of insulin pumps and continuous glucose monitoring in the hospital. Diabetes Care. 2018; 41 (8): 1579- 1589.

[60] Reznik Y , Cohen O , Aronson R , et al. Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (opt2mise):a randomised open-label controlled trial. Lancet (London, England). 2014; 384 (9950): 1265- 1272.

[61] Aronson R , Reznik Y , Conget I , et al. Sustained efficacy of insulin pump therapy compared with multiple daily injections in type 2 diabetes:12-month data from the opt2mise randomized trial. Diabetes Obes Metabol. 2016; 18 (5): 500- 507.

[62] Huang X , Li S , Yang M , et al. The effects of short-term continuous subcutaneous insulin infusion treatment on fasting glucagon-like peptide-1 concentrations in newly diagnosed type 2 diabetes. Diabetes Res Clin Pract. 2018; 138: 246- 252.

[63] Liu L , Liu J , Xu L , et al. Lower mean blood glucose during short-term intensive insulin therapy is associated with long-term glycemic remission in patients with newly diagnosed type 2 diabetes:evidence-based recommendations for standardization. Journal of Diabetes Investigation. 2018; 9 (4): 908- 916.

[64] Hermanns N , Lilly LC , Mader JK , et al. Novel simple insulin delivery device reduces barriers to insulin therapy in type 2 diabetes. J Diabetes Sci Technol. 2015; 9 (3): 581- 587.

[65] Reznik Y , Cohen O . Insulin pump for type 2 diabetes. Diabetes Care. 2013; 36 (Suppl 2): S219- S225.

[66] Pickup JC . Insulin pumps. Diabetes Technol Therapeut. 2018; 20 (S1): S30- S40.

[67] Chamberlain JJ , Gilgen E . Do perceptions of insulin pump usability impact attitudes toward insulin pump therapy? a pilot study of individuals with type 1 and insulintreated type 2 diabetes. J Diabetes Sci Technol. 2014; 9 (1): 105- 110.

[68] American Diabetes Association . Continuous subcutaneous insulin infusion. Diabetes Care. 2004; 27 (suppl ) S110.

[69] Ehrmann D , Kulzer B , Schipfer M , et al. Efficacy of an education program for people with diabetes and insulin pump treatment (input):results from a randomized controlled trial. Diabetes Care. 2018; 41 (12): 2453- 2462.

[70] Ginsberg BH . Patch pumps for insulin. J Diabetes Sci Technol. 2019; 13 (1): 27- 33.

[71] Mader JK , Lilly LC , Aberer F , et al. Improved glycaemic control and treatment satisfaction with a simple wearable 3-day insulin delivery device among people with type 2 diabetes. Diabet Med. 2018; 35 (10): 1448- 1456.

[72] Bergenstal RM , Johnson ML , Aroda VR , et al. Comparing patch vs pen bolus insulin delivery in type 2 diabetes using continuous glucose monitoring metrics and profiles. J Diabetes Sci Technol. 2022; 16 (5): 1167- 1173.

[73] Lilly LC , Mader JK , Warner J . Developing a simple 3-day insulin delivery device to meet the needs of people with type 2 diabetes. J Diabetes Sci Technol. 2019; 13 (1): 11- 19.

[74] Sutton D , Higdon CD , Nikkel C , et al. Clinical benefits over time associated with use of v-go wearable insulin delivery device in adult patients with diabetes:a retrospective analysis. Adv Ther. 2018; 35 (5): 631- 643.

[75] Everitt B , Harrison HC , Nikkel C , et al. Clinical and economic considerations based on persistency with a novel insulin delivery device versus conventional insulin delivery in patients with type 2 diabetes:a retrospective analysis. Res Soc Adm Pharm:RSAP. 2019; 15 (9): 1126- 1132.

[76] Raval AD , Nguyen MH , Zhou S , et al. Effect of v-go versus multiple daily injections on glycemic control, insulin use, and diabetes medication costs among individuals with type 2 diabetes mellitus. Journal of Managed Care & Specialty Pharmacy. 2019; 25 (10): 1111- 1123.

[77] Johns BR , Jones TC , Sink JH , et al. Real-world assessment of glycemic control after vgo^® initiation in an endocrine practice in the southeastern United States. J Diabetes Sci Technol. 2014; 8 (5): 1060- 1061.

[78] Skajaa GØ , Fuglsang J , Kampmann U , et al. Parity increases insulin requirements in pregnant women with type 1 diabetes. J Clin Endocrinol Metabol. 2018; 103 (6): 2302- 2308.

[79] Farrar D , Tuffnell DJ , West J . Continuous subcutaneous insulin infusion versus multiple daily injections of insulin for pregnant women with diabetes. Cochrane Database Syst Rev. 2007; (3): CD005542.

[80] Feig DS , Corcoy R , Donovan LE , et al. Pumps or multiple daily injections in pregnancy involving type 1 diabetes:a prespecified analysis of the conceptt randomized trial. Diabetes Care. 2018; 41 (12): 2471- 2479.

[81] Cheisson G , Jacqueminet S , Cosson E , et al. Perioperative management of adult diabetic patients. intraoperative period. Anaesthesia. Critical Care & Pain Medicine. 2018; 37 (Suppl 1): S21- S25.

[82] Umpierrez GE , Smiley D , Jacobs S , et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (rabbit 2 surgery). Diabetes Care. 2011; 34 (2): 256- 261.

[83] Clement S , Braithwaite SS , Magee MF , et al. Management of diabetes and hyperglycemia in hospitals. Diabetes Care. 2004; 27 (2): 553- 591.

[84] Avanzini F , Marelli G , Donzelli W , et al. Transition from intravenous to subcutaneous insulin:effectiveness and safety of a standardized protocol and predictors of outcome in patients with acute coronary syndrome. Diabetes Care. 2011; 34 (7): 1445- 1450.

[85] Schmeltz LR , DeSantis AJ , Thiyagarajan V , et al. Reduction of surgical mortality and morbidity in diabetic patients undergoing cardiac surgery with a combined intravenous and subcutaneous insulin glucose management strategy. Diabetes Care. 2007; 30 (4): 823- 828.

[86] Lazar HL . Glycemic control during coronary artery bypass graft surgery. Int Sch Res Not. 2012; 2012 (1): 292490.

[87] Cheisson G , Jacqueminet S , Cosson E , et al. Perioperative management of adult diabetic patients. postoperative period. Anaesthesia. Critical Care & Pain Medicine. 2018; 37 (Suppl 1): S27- S30.

RIGHTS & PERMISSIONS

The Authors. Publishing services by Elsevier B.V. on behalf of Higher Education Press and KeAi Communications Co. Ltd.